cellcard cellcard cellcard

COVID-19: A status update on the leading coronavirus vaccine candidates around the world

Share:

Some of the frontrunners of coronavirus vaccine race include Pfizer-BioNTech, Oxford-AstraZeneca, Sputnik V, and Moderna Inc’s vaccine candidates, respectively.

As researchers and medical professionals work tirelessly, around the clock to find an effective and safe jab against the novel coronavirus infection, the disease caused by SARS-CoV-2, the race is intensifying. With more than 200 vaccine candidates under development against COVID-19, some of them have emerged as frontrunners and are raising hopes of the world population that the pandemic may soon see an end.

Some of these frontrunners include Pfizer-BioNTech, Oxford-AstraZeneca, Sputnik V, and Moderna Inc’s vaccine candidates, respectively. Let us take a look at the latest updates from these vaccines, and where they stand currently in the race.

Pfizer-BioNTech approved for use by Britain

In a historic move, Britain has become the first country in the world to approve the Pfizer-BioNTech coronavirus vaccine. They have said that the vaccine will be rolled out from next week onwards.

Pfizer-BioNTech have prepared a COVID-19 vaccine in partnership with each other. While last week they declared that the vaccine was 95 per cent effective, in another step forward, they have filed for emergency use authorization in Europe. Reports of Pfizer filing for emergency use authorization from the US FDA had come out, soon after the announcement on efficacy.

Moderna files of emergency use authorization in the US, Europe

Soon before Pfizer-BioNTech said that they will file for emergency use in Europe, Moderna had announced that their vaccine candidate was 94.1 per cent effective in COVID-19, while a hundred per cent effective in severe COVID-19. They had also said that they will be immediately filing for emergency use approval in the US, as well as Europe, on Monday.

Sputnik V vaccine trials commence in India

Sputnik V has been one of the most talked-about vaccine candidates around the world. The vaccine became the first, globally, to be approved for public use. However, trials of the vaccine are still underway. Interim analysis has found that the vaccine is about 95 per cent effective in preventing COVID-19. Dr Reddy’s Laboratories is testing the vaccine in India, and trials have now commenced in the country.

The Oxford-AstraZeneca COVID-19 vaccine: Serum Institute vs Trial participant from Chennai

The Oxford-AstraZeneca COVID-19 vaccine has recently been talked about because of the spat between the Serum Insitute of India, and a vaccine trial participant from Chennai, India. The participant has alleged that he suffered from severe neurological symptoms due to the vaccine. However, SII has denied all claims and said that this is being done to malign the reputation of the institute. The matter is currently being looked into by the Drug Controller General of India. Legal notices from both ends have been issued to the respective parties.

Meanwhile, Adar Poonawala, CEO of Serum Insitute had recently said that they plan on filing for emergency use authorization in India, in about two weeks time. Times Now, India

Related Posts

Previous Article

Trump floats idea of 2024 White House run

Next Article

DRAFT landscape of COVID-19 candidate vaccines – 2 December 2020